<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3643086</article-id><article-id pub-id-type="publisher-id">cc11999</article-id><article-id pub-id-type="doi">10.1186/cc11999</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>A clinical randomized trial on the use of atorvastatin in patients with sepsis or septic shock: effects on endothelial function</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Prado</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Ribeiro</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Furian</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Pinto Ribeiro</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Silvello</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Rohde</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Clausell</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Becker</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Hospital de Clinicas de Porto Alegre, Brazil</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2013</year></pub-date><volume>17</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">33rd International Symposium on Intensive Care and Emergency Medicine</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by ISICEM</named-content></supplement><fpage>P61</fpage><lpage>P61</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Prado et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Prado et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/17/S2/P61"/><conference><conf-date>19-22 March 2013</conf-date><conf-name>33rd International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Sepsis and septic shock are complex inflammatory syndromes. Multiple cellular activation processes are involved, and many humoral cascades are triggered. Presumably, endothelial cells play a pivotal rule in the pathogenesis of sepsis, not only because they may influence the inflammatory cascade but also because, upon interaction with excessive amounts of inflammatory mediators, the function of these cells may become impaired. It is likely that a general dysfunction of the endothelium is a key event in the pathogenesis of sepsis [<xref ref-type="bibr" rid="B1">1</xref>]. HMG-CoA-reductase inhibitors have been shown to exhibit pronounced immunomodulatory effects independent of lipid lowering. Most of these beneficial effects of statins appear to involve restoring or improving endothelial function [<xref ref-type="bibr" rid="B2">2</xref>]. We hypothesize that statins can improve endothelial dysfunction in septic patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>A double-blinded, placebo-controlled, randomized trial was undertaken. We enrolled adult patients within 24 hours of severe sepsis or septic shock diagnosis and randomized them to placebo or atorvastatin 80 mg/day for a short term. Endothelial dysfunction was assessed measuring plasmatic levels of IL-6, ET-1, VCAM-1 by ELISA and measuring flow-mediated vasodilatation of the brachial artery at basal, 24 and 72 hours after randomization.</p></sec><sec sec-type="results"><title>Results</title><p>We studied 47 patients, 24 in the placebo group (mean age 52 &#x000b1; 20 years, 29.1% male; APACHE II risk score 23.5 &#x000b1; 7.3) and 23 in the statin group (mean age 49.5 &#x000b1; 18 years, 53.4% male; APACHE II risk score 23 &#x000b1; 6.9). The baseline characteristics of the placebo group were similar to statin patients as well as the mean length of stay in the ICU (8.6 &#x000b1; 7.4 and 9.1 &#x000b1; 8 days, respectively) and the time on vasopressors (49.3 &#x000b1; 47.1 and 59 &#x000b1; 91.1 hours, respectively). No significant difference was observed on the temporal variation of biomarker levels (IL-6, VCAM-1, ET-1) between treatment and control groups. The intrahospital mortality rate was 26% in the statin group and 45% in the placebo group (<italic>P </italic>= 0.17).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our data showed no benefit with the use of a potent statin acutely in patients with sepsis or septic shock with regards to improvement in endothelial function.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Hack</surname><given-names>EC</given-names></name><etal/><article-title>The endothelium in sepsis: source of and a target for inflammation</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>S21</fpage><lpage>S27</lpage><pub-id pub-id-type="pmid">11445730</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Davignon</surname><given-names>J</given-names></name><article-title>Beneficial cardiovascular pleiotropic effects of statins</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>Suppl III</issue><fpage>III-39</fpage><lpage>III-43</lpage><pub-id pub-id-type="pmid">15198965</pub-id></mixed-citation></ref></ref-list></back></article>